BioCentury
ARTICLE | Clinical News

IV CR845: Clinical trial data

November 10, 2014 8:00 AM UTC

Top-line data from a double-blind, active- and placebo-controlled, crossover human abuse liability trial in 40 non-dependent, recreational polydrug users with lifetime and recent hallucinogenic drug use showed that IV CR845 at therapeutic and supratherapeutic doses each met the primary endpoint of reducing "drug liking" scores as measured by a visual analog scale (VAS) vs. IV pentazocine (p<0.0001). IV CR845 also significantly reduced "feeling high" and "overall liking" scores vs. IV pentazocine (p<0.0001 for both). Additionally, both doses of IV CR845 were rated equivalent to placebo on "overall drug liking" and "take drug again" measures. Cara said the data suggest the potential for CR845 to be the first schedule V controlled substance or non-scheduled peripheral opioid for acute pain. The generic pentazocine is a schedule IV mixed OPRK1 and mu opioid receptor ( OPRM1; MOR) agonist. ...